Orbimed Advisors LLC Rapt Therapeutics, Inc. Transaction History
Orbimed Advisors LLC
- $3.21 Billion
- Q1 2025
A detailed history of Orbimed Advisors LLC transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 13,135,260 shares of RAPT stock, worth $129 Million. This represents 0.5% of its overall portfolio holdings.
Number of Shares
13,135,260
Previous 13,135,260
-0.0%
Holding current value
$129 Million
Previous $20.8 Million
22.78%
% of portfolio
0.5%
Previous 0.56%
Shares
7 transactions
Others Institutions Holding RAPT
# of Institutions
71Shares Held
100MCall Options Held
41.3KPut Options Held
100-
Tcg Crossover Management, LLC Palo Alto, CA13.1MShares$128 Million3.85% of portfolio
-
Foresite Capital Management Vi LLC Larkspur, CA12.5MShares$123 Million8.35% of portfolio
-
Rtw Investments, LP New York, NY11.8MShares$115 Million0.24% of portfolio
-
Bvf Inc San Francisco, CA9.24MShares$90.6 Million0.5% of portfolio
-
Redmile Group, LLC San Francisco, CA6.48MShares$63.5 Million0.83% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $291M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...